Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

Introduction Amongst the 25.7 million survivors and 6.5 million deaths from stroke between
1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases …

Background Atrial fibrillation (AF) associated ischemic stroke is associated with worse
functional outcomes, less effective recanalization, and increased rates of hemorrhagic …

Background: The occurrence of both ischaemic (IS) and haemorrhagic stroke in patients on
anticoagulation is a major issue due to the frequency of their prescriptions in westernised …

Introduction Since approval by the United States Food and Drug Administration in 1996,
alteplase utilization rates for acute ischemic stroke have increased. Despite its efficacy for …

Introduction The number of patients with left ventricular assist devices (LVAD) is rapidly
growing in industrialized countries. While cerebrovascular events comprise a significant …

Background and objectives Oral anticoagulants prevent thromboembolic events but expose
patients to a significant risk of bleeding due to the treatment itself, after trauma, or during …

Antithrombotic drugs (ADs) are the mainstay of secondary prevention of thrombotic vascular
diseases. Management of patients under long-term treatment with ADs admitted for acute …

Introduction Based on demographical trends and the expected worldwide increase in the
number of individuals with atrial fibrillation, the rate of patients who are on oral …

En raison de l'augmentation de l'utilisation des anticoagulants dans la population ces
dernières années, la prise en charge de ces patients est devenue une pratique quotidienne …